Royal Bank Of Canada Has Lowered Expectations for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price objective cut by Royal Bank Of Canada to $1.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 119.30% from the stock’s current price.

EYPT has been the topic of several other research reports. Cantor Fitzgerald lowered shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Monday, August 17th. Jefferies Financial Group lowered Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a research report on Monday. Wall Street Zen raised Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 27th. Citigroup cut their target price on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a research note on Tuesday, August 18th. Finally, HC Wainwright restated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $21.85.

Eyepoint Pharmaceuticals Trading Up 3.6%

Eyepoint Pharmaceuticals stock traded up $0.02 during midday trading on Tuesday, hitting $0.46. 28,509,621 shares of the stock were exchanged, compared to its average volume of 3,175,864. The stock’s 50-day simple moving average is $4.77 and its 200 day simple moving average is $10.30. Eyepoint Pharmaceuticals has a fifty-two week low of $0.40 and a fifty-two week high of $19.11. The stock has a market capitalization of $39.31 million, a price-to-earnings ratio of -0.12 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The firm had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. Equities analysts anticipate that Eyepoint Pharmaceuticals will post -3.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Cyndeo Wealth Partners LLC increased its stake in Eyepoint Pharmaceuticals by 46.8% during the third quarter. Cyndeo Wealth Partners LLC now owns 35,519 shares of the company’s stock worth $116,000 after purchasing an additional 11,329 shares during the period. Engineers Gate Manager LP acquired a new stake in shares of Eyepoint Pharmaceuticals during the second quarter worth about $161,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Eyepoint Pharmaceuticals during the second quarter worth about $72,000. Squarepoint Ops LLC increased its stake in Eyepoint Pharmaceuticals by 22.3% during the 2nd quarter. Squarepoint Ops LLC now owns 98,002 shares of the company’s stock worth $1,401,000 after buying an additional 17,883 shares during the period. Finally, Baird Financial Group Inc. lifted its holdings in Eyepoint Pharmaceuticals by 16.4% during the 2nd quarter. Baird Financial Group Inc. now owns 32,732 shares of the company’s stock worth $468,000 after buying an additional 4,613 shares in the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

Key Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Royal Bank of Canada said upcoming data from EyePoint’s diabetic macular edema (DME) study could provide a catalyst after the Phase 3 LUCIA trial in wAMD missed its primary endpoint. RBC maintained a “sector perform” rating but lowered its price target to $1.00, implying substantial potential upside from current levels. EyePoint’s DME Study Readout a Catalyst After wAMD Trial Misses Endpoint, RBC Says
• Positive Sentiment: EyePoint is prioritizing its late-stage DURAVYU program in DME, a move intended to reduce spending and concentrate resources on the company’s remaining major clinical opportunity. EyePoint Announces Strategic Prioritization
• Positive Sentiment: Trading activity included unusually high call-option volume, with 7,885 calls purchased—about 69% above typical daily volume—suggesting some speculative traders are positioning for a recovery, although this is not a fundamental improvement.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.